Erratum: Novel lipid-lowering therapies to reduce cardiovascular risk (JAMA (2021) 326:3 (266-267) DOI: 10.1001/jama.2021.2244)

Research output: Contribution to journalComment/debatepeer-review

Abstract

Incorrect Classification of Pharmaceutical Agent: In the JAMA Insights article titled "Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk,"published July 20, 2021,1 therewas an error in nomenclature. Inclisiran is described as an antisense olignonucleotide, which is incorrect. Inclisiran is a small interfering RNA (siRNA) molecule that interferes with translation ofPCSK-9mRNA. This articlewas corrected online.

Original languageEnglish (US)
Pages (from-to)873
Number of pages1
JournalJAMA - Journal of the American Medical Association
Volume326
Issue number9
DOIs
StatePublished - Sep 7 2021

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Erratum: Novel lipid-lowering therapies to reduce cardiovascular risk (JAMA (2021) 326:3 (266-267) DOI: 10.1001/jama.2021.2244)'. Together they form a unique fingerprint.

Cite this